Volume | 379,195 |
|
|||||
News | (1) | ||||||
Day High | 69.59 | Low High |
|||||
Day Low | 68.07 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Dr Reddys Laboratories Ltd | RDY | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
69.50 | 68.07 | 69.59 | 68.68 | 69.86 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
5,894 | 379,195 | US$ 68.66 | US$ 26,036,747 | - | 54.48 - 77.72 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:00:00 | 83,988 | US$ 68.68 | USD |
Dr Reddys Laboratories Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
0 | 166.53M | - | 289.05B | 55.78B | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dr Reddys Laboratories News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RDY Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 69.60 | 71.49 | 68.07 | 70.21 | 317,598 | -0.92 | -1.32% |
1 Month | 74.89 | 75.43 | 68.07 | 70.09 | 293,953 | -6.21 | -8.29% |
3 Months | 76.35 | 77.29 | 68.07 | 71.96 | 219,395 | -7.67 | -10.05% |
6 Months | 69.00 | 77.72 | 64.50 | 71.24 | 230,914 | -0.32 | -0.46% |
1 Year | 54.48 | 77.72 | 54.48 | 68.65 | 243,774 | 14.20 | 26.06% |
3 Years | 72.51 | 77.72 | 47.88 | 61.54 | 203,008 | -3.83 | -5.28% |
5 Years | 38.23 | 77.72 | 33.33 | 57.81 | 196,764 | 30.45 | 79.65% |
Dr Reddys Laboratories Description
Headquartered in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceutical products sold across the world. The company specializes in low-cost, easy-to-produce small-molecule generic drugs and active pharmaceutical ingredients. Its drug portfolio in recent years has included biosimilar drug launches in select emerging markets and has shifted toward injectables and more complex generic products. Geographically, the company's sales are well dispersed across North America, India, and other emerging markets. |